CGM study: basal-insulin users see measurable HbA1c reductions
- The FreeDM2 trial, led by Emma Wilmot and Lala Leelarathna, showed real-time CGM beat finger-prick monitoring in 303 adults with type 2 diabetes using basal insulin. (nottingham.ac.uk) - HbA1c started at 8.8% in both groups, then fell to 7.8% with CGM versus 8.3% in controls by week 32 — a 0.5-point advantage. (renalandurologynews.com) - That matters because CGM access has often centered on intensive insulin users, while 2026 diabetes guidance is moving toward broader technology use. (nottingham.ac.uk)
Continuous glucose monitoring is a sensor story, but really it’s a behavior story. The device sits on the arm and shows glucose in near real time. That sounds simple. But for people to act fast enough to change what they do today, not three months later at the next HbA1c check. That’s why the new FreeDM2 trial matters — it tested whether real-time CGM can help this less-intensive insulin group, and the answer was yes. ### Who was actually studied? The trial enrolled 303 adults with type 2 diabetes in the UK. Everyone was on other glucose-lowering drugs like SGLT2 inhibitors or GLP-1–based therapies. Their starting HbA1c ranged from 7.5% to 11.0%, so this was a group with room to improve but not the most complex insulin regimen. ### What did the trial compare? Researchers randomized participants 198 to CGM and 105 to standard self-monitoring with finger-prick blood glucose checks. The study ran for 16 weeks of intervention, then another 16 weeks when clinicians could add therapies under national guidance. That setup matters because it tested both the “can people use this on their own?” question and the “does the benefit last once routine care gets involved?” question. The difference favored the CGM group — an adjusted difference of 0.6 percentage points. By week 32, the CGM group was down to 7.8% while controls reached 8.3%, leaving a 0.5-point gap. In diabetes care, half a point is not magic, but it is real — especially in a group not using full intensive insulin therapy. ### Why would a sensor help basal-insulin users? Because basal insulin is blunt. It couldn't show what breakfast did, what a walk changed, or whether overnight glucose is drifting up. Basically, the device turns diabetes management from guesswork into pattern recognition. The trial team said many participants described that feedback as life changing. ### Was there any severe hypoglycemia? That doesn’t prove CGM eliminates severe lows in this population, but it does suggest the glucose gains did not come with an obvious safety penalty in the trial. ### Why is this a bigger deal than one trial? Because CGM policy has long favored people on multiple daily injections or pumps. Bas
